Salvia BioElectronics

Salvia BioElectronics is a private, clinical-stage MedTech company developing an implantable bioelectronic neuromodulation system for chronic migraine and cluster headache. The company's core technology, MySalvia Therapy, consists of ultra-thin implants targeting key nerves and a wearable device for patient activation, aiming to provide a drug-free treatment option. Backed by a recent $60M Series B financing, Salvia is advancing clinical studies from its base at the High Tech Campus in Eindhoven. The company operates pre-revenue, with its therapy not yet approved for commercial use.

MySalvia Therapy: An implantable bioelectronic neuromodulation system featuring ultra-thin implants targeting peripheral nerves involved in headache disorders, activated by a patient-controlled wearable device for on-demand, drug-free relief.

Salvia competes in the migraine therapy space against large pharmaceutical companies (with CGRP inhibitors, etc.) and other neuromodulation device companies offering both external (e.g., Cefaly, gammaCore) and implantable (e.g., SPR Therapeutics, Abbott's BurstDR) systems. Its ultra-thin, patient-activated implant aims to differentiate on minimal invasiveness and user control.